{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:22:20Z","timestamp":1785252140690,"version":"3.55.0"},"reference-count":201,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2019296"],"award-info":[{"award-number":["2019296"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100025520","name":"Medical Research Future Fund","doi-asserted-by":"publisher","award":["APP1199620"],"award-info":[{"award-number":["APP1199620"]}],"id":[{"id":"10.13039\/501100025520","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118885","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:44:31Z","timestamp":1765007071000},"page":"118885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Drug repurposing in gynaecological cancers: Proven drugs for new challenges"],"prefix":"10.1016","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2308-0256","authenticated-orcid":false,"given":"Amani","family":"Alghalayini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0990-1796","authenticated-orcid":false,"given":"Farhana A.","family":"Sarker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie-Ann","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola A.","family":"Bowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5899-4931","authenticated-orcid":false,"given":"Deborah J.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib1","first-page":"128","article-title":"Wanqing Chen,Comparative Study of Cancer Profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN)","volume":"4","author":"Cao","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"issue":"12","key":"10.1016\/j.biopha.2025.118885_bib2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.trecan.2020.07.007","article-title":"\"Human-Derived Model Systems In Gynecological Cancer Research","volume":"6","author":"L\u00f5hmussaar","year":"2020","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib3","first-page":"229","article-title":"\"Global cancer statistics 2022: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA a cancer journal clinicians"},{"issue":"7","key":"10.1016\/j.biopha.2025.118885_bib4","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41571-024-00904-z","article-title":"\"Epidemiology of Hpv-associated cancers past, present and future: towards prevention and elimination","volume":"21","author":"Malagon","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib5","first-page":"1","article-title":"\"Prevention, screening, treatment and follow-up of gynecological cancers. State of art and future perspectives.\"","volume":"8","author":"Tullio","year":"2023","journal-title":"Clin. Exp. Obstet. Gynecol. 50"},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/joim.13709","article-title":"\"Precision cancer medicine: concepts, current practice, and future developments","volume":"294","author":"Edsj\u00f6","year":"2023","journal-title":"J. Intern. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s10555-023-10113-2","article-title":"\"New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions","volume":"42","author":"Zhang","year":"2023","journal-title":"Cancer Metastas.. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118885_bib8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib9","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/15384047.2022.2046450","article-title":"\"Mllt11-tril complex promotes the progression of endometrial cancer through Pi3k\/Akt\/Mtor Signaling Pathway","volume":"23","author":"Liao","year":"2022","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib10","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/1389450120666191120123612","article-title":"\"The Potential of Pi3k\/Akt\/Mtor signaling as a druggable target for endometrial and ovarian carcinomas","volume":"21","author":"Lengyel","year":"2020","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000152","article-title":"\"Endometrial cancer: molecular classification and future treatments","volume":"1","author":"Corr","year":"2022","journal-title":"BMJ Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"\"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Cha","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"\"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2025.118885_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102204","article-title":"\"Redefining cancer of unknown primary: is precision medicine really shifting the paradigm?\"","volume":"97","author":"Olivier","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118885_bib16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"\"Estimated research and development investment needed to bring a new medicine to market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2025.118885_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"\"How much does it cost to research and develop a new drug? a systematic review and assessment","volume":"39","author":"Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/1535370219839163","article-title":"\"Cancer drug development: the missing links","volume":"244","author":"Kunnumakkara","year":"2019","journal-title":"Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib19","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.drudis.2021.12.021","article-title":"\"An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020","volume":"27","author":"Wang","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.biopha.2025.118885_bib20","article-title":"\"Drugbank. Statistics","year":"2025","journal-title":"Drug. Online"},{"key":"10.1016\/j.biopha.2025.118885_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"\"Innovation in the pharmaceutical industry: new estimates of R&D Costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.biopha.2025.118885_bib22","doi-asserted-by":"crossref","unstructured":"Nosengo, Nicola. \"Can You Teach Old Drugs New Tricks?\": Nature Publishing Group UK London, 2016.","DOI":"10.1038\/534314a"},{"key":"10.1016\/j.biopha.2025.118885_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113432","article-title":"\"Virtual screening of substances used in the treatment of sars-cov-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses","volume":"153","author":"Negru","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib24","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/341362","article-title":"\"Drug repositioning for gynecologic tumors: a new therapeutic strategy for cancer","volume":"2015","author":"Banno","year":"2015","journal-title":"Sci. World J."},{"key":"10.1016\/j.biopha.2025.118885_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2020.03.005","article-title":"\"Old Drugs, new uses: drug repurposing in hematological malignancies","author":"Kale","year":"2021","journal-title":"Pap. Presente Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"\"Drug Repositioning: Identifying And Developing New Uses For Existing Drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118885_bib27","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.actatropica.2016.11.006","article-title":"\"Repositioning of chlorambucil as a potential anti-schistosomal agent","volume":"166","author":"Eissa","year":"2017","journal-title":"Acta Trop."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib28","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.leu.2403285","article-title":"Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma","volume":"18","author":"Kumar","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.biopha.2025.118885_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105705","article-title":"\"The new paradigm in animal testing\u2013\u201c3rs alternatives","author":"Poh","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118885_bib30","unstructured":"Food, U.S., and Drug Administration. \"Fda Announces Plan to Phase out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs.\" US Food and Drug Administration: Silver Spring, MD, USA (2025)."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41573-022-00633-x","article-title":"\"The evolving role of investigative toxicology in the pharmaceutical Industry","volume":"22","author":"Pognan","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib32","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s12015-024-10701-x","article-title":"\"Alternatives of animal models for biomedical research: a comprehensive review of modern approaches","volume":"20","author":"Vashishat","year":"2024","journal-title":"Stem Cell Rev. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"\"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s42256-020-00276-w","article-title":"\"A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data","volume":"3","author":"Liu","year":"2021","journal-title":"Nat. Mach. Intell."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41585-022-00677-z","article-title":"\"Experimental in vitro, ex vivo and in vivo models in prostate cancer research","volume":"20","author":"Sailer","year":"2023","journal-title":"Nat. Rev. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/srep28951","article-title":"\"Capturing tumor complexity in vitro: comparative analysis of 2d and 3d tumor models for drug discovery","volume":"6","author":"Stock","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13020-024-00956-4","article-title":"\"Lab-on-a-chip: an advanced technology for the modernization of traditional Chinese medicine","volume":"19","author":"Lu","year":"2024","journal-title":"Chin. Med."},{"key":"10.1016\/j.biopha.2025.118885_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152667","article-title":"\"A 3d microfluidic liver model for high throughput compound toxicity screening in the organoplate\u00ae","volume":"450","author":"Bircsak","year":"2021","journal-title":"Toxicology"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib39","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ygyno.2014.11.078","article-title":"\"Updates and emerging therapies for rare epithelial ovarian cancers: one size no longer fits all","volume":"136","author":"Groen","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.msec.2014.06.002","article-title":"\"Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: a review","volume":"45","author":"Ye","year":"2014","journal-title":"Materials Science Engineering C"},{"key":"10.1016\/j.biopha.2025.118885_bib41","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.thromres.2018.01.030","article-title":"\"Anti-angiogenesis for cancer: current status and prospects","volume":"164","author":"Russo","year":"2018","journal-title":"Thromb. Res."},{"key":"10.1016\/j.biopha.2025.118885_bib42","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/bs.pmbts.2016.10.002","article-title":"Dysregulation of aromatase in breast, endometrial, and ovarian cancers: an overview of therapeutic strategies","volume":"144","author":"Manna","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118885_bib43","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"\"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib44","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"\"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118885_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/papr.12198","article-title":"\"Ketorolac tromethamine\u2013routes and clinical implications","volume":"2","author":"Vadivelu","year":"2015","journal-title":"Pain. Pract. 15"},{"key":"10.1016\/j.biopha.2025.118885_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07716-1","article-title":"\"The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo","volume":"21","author":"Grimes","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2025.118885_bib47","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.2147\/OTT.S223119","article-title":"\"Inhibition of the hedgehog pathway for the treatment of cancer using itraconazole","author":"Li","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/2767-9764.CRC-22-0037","article-title":"\"Repurposing itraconazole and hydroxychloroquine to target lysosomal homeostasis in epithelial ovarian cancer","volume":"2","author":"Marastoni","year":"2022","journal-title":"Cancer Res. Commun."},{"issue":"14","key":"10.1016\/j.biopha.2025.118885_bib49","first-page":"1845","article-title":"\"Gene expression\u2013based discovery of atovaquone as a stat3 inhibitor and anticancer agent","volume":"128","author":"Xiang","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib50","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-18-1286","article-title":"\"Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting her2\/\u03b2-catenin signaling","volume":"18","author":"Gupta","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2025.118885_bib51","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5631","article-title":"\"Repurposing atovaquone as a stat3 inhibitor for the treatment of platinum resistant ovarian cancer","author":"Wood","year":"2024","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib52","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ijgc-2018-000060","article-title":"\"Association of metformin use with ovarian cancer incidence and prognosis: a systematic review and meta-analysis","volume":"29","author":"Shi","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.118885_bib53","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","article-title":"\"Metformin: historical overview","volume":"60","author":"Bailey","year":"2017","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.biopha.2025.118885_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0b013e3182a80a21","article-title":"\"The effects of metformin on ovarian cancer: a systematic review","volume":"23","author":"Dilokthornsakul","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2012.07.115","article-title":"\"Metformin targets ovarian cancer stem cells in vitro and in vivo","volume":"127","author":"Shank","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib56","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133247","article-title":"\"Phase Ii clinical trial of metformin as a cancer stem cell\u2013targeting agent in ovarian cancer","author":"Brown","year":"2020","journal-title":"JCI Insight 5 no. 11"},{"key":"10.1016\/j.biopha.2025.118885_bib57","series-title":"Cancer Network","article-title":"Trastuzumab Deruxtecan Showcases Clinical Efficacy in Her2+ Gynecological Cancers","author":"Mauro","year":"2023"},{"key":"10.1016\/j.biopha.2025.118885_bib58","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1016\/j.ygyno.2024.07.442","article-title":"\"Phase Ii basket study of disitamab vedotin among patients with previously-treated, locally advanced unresectable or metastatic solid tumors that express her2: ovarian and endometrial cancer cohorts (Dv-005; Trial in Progress)","volume":"190","author":"Liu","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib59","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5514","article-title":"\"A Phase Ii trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with Er\/Pr-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: Lacog 1018","author":"Damian","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib60","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ygyno.2024.07.112","article-title":"\"A Phase Ii study of weekly paclitaxel, lenvatinib and pembrolizumab among patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal cancer","volume":"190","author":"Backes","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2025.118885_bib61","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1200\/JCO.23.02076","article-title":"\"Phase I and randomized phase Ii study of ruxolitinib with frontline neoadjuvant therapy in advanced ovarian cancer: an nrg oncology group study","volume":"42","author":"Landen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib62","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-199754010-00007","article-title":"\"Nelfinavir","volume":"54","author":"Perry","year":"1997","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib63","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4161\/cbt.8.3.7339","article-title":"\"Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in er vacuolization, cell cycle retardation and apoptosis","volume":"8","author":"Br\u00fcning","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/cancers14010099","volume":"14","author":"Subeha","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.biopha.2025.118885_bib65","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1158\/1078-0432.CCR-05-1167","article-title":"\"Effects of hiv protease inhibitor ritonavir on akt-regulated cell proliferation in breast cancer","volume":"12","author":"Srirangam","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib66","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.3390\/curroncol31100450","article-title":"\"Ritonavir\u2019s evolving role: a journey from antiretroviral therapy to broader medical applications","volume":"31","author":"Pereira","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-8-26","article-title":"\"Ritonavir blocks akt signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells","volume":"8","author":"Kumar","year":"2009","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3748\/wjg.v17.i4.419","article-title":"\"Peginterferon and ribavirin treatment for hepatitis C Virus Infection","volume":"17","author":"Tsubota","year":"2011","journal-title":"World J. Gastroenterol. WJG"},{"key":"10.1016\/j.biopha.2025.118885_bib69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"\"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib70","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.bbrc.2019.01.117","article-title":"\"Targeting eif4e signaling with ribavirin as a sensitizing strategy for ovarian cancer","volume":"510","author":"Jin","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib71","article-title":"\"Drug repurposing screen targeting parp identifies cytotoxic activity of efavirenz in high-grade serous ovarian cancer","volume":"32","author":"Matthews","year":"2024","journal-title":"Mol. Ther. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118885_bib72","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"\"Ivermectin\u2013old drug, new tricks?\"","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib73","first-page":"317","article-title":"\"The Multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug","volume":"8","author":"Juarez","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118885_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105207","article-title":"\"Ivermectin, a potential anticancer drug derived from an antiparasitic drug","volume":"163","author":"Tang","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib75","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13167-020-00209-y","article-title":"\"Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncrna-eif4a3-mrna axes","volume":"11","author":"Li","year":"2020","journal-title":"EPMA J."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.amjms.2019.11.001","article-title":"\"Ivermectin augments the in vitro and in vivo efficacy of cisplatin in epithelial ovarian cancer by suppressing akt\/mtor signaling","volume":"359","author":"Zhang","year":"2020","journal-title":"Am. J. Med. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib77","doi-asserted-by":"crossref","first-page":"582","DOI":"10.7326\/0003-4819-91-4-582","article-title":"Drugs five years later: mebendazole","volume":"91","author":"Keystone","year":"1979","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib78","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ygyno.2020.10.010","article-title":"\"Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer","volume":"160","author":"Elayapillai","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib79","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.2147\/IJN.S458910","article-title":"\"Pharmacology progresses and applications of chloroquine in cancer therapy","author":"Liu","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2025.118885_bib80","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41419-020-03242-x","article-title":"\"Chloroquine reverses chemoresistance via upregulation of p21waf1\/cip1 and autophagy inhibition in ovarian cancer.\"","volume":"12","author":"Hwang","year":"2020","journal-title":"Cell Death Dis. 11"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib81","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00280-020-04216-8","article-title":"\"Disulfiram: a novel repurposed drug for cancer therapy","volume":"87","author":"Lu","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118885_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.762820","article-title":"\"Disulfiram transcends aldh inhibitory activity when targeting ovarian cancer tumor-initiating cells","volume":"12","author":"Caminear","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib83","article-title":"\"Combined treatment of disulfiram with parp inhibitors suppresses ovarian cancer","volume":"13","author":"Tang","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6904-2-1","article-title":"\"Ldl-Cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (zocor\u2122) in thai hypercholesterolemic subjects\u2013a randomized crossover study, the first report from Thailand","volume":"2","author":"Wiwanitkit","year":"2002","journal-title":"BMC Clin. Pharmacol."},{"issue":"40","key":"10.1016\/j.biopha.2025.118885_bib85","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.18632\/oncotarget.27747","article-title":"\"Simvastatin is a potential candidate drug in ovarian clear cell carcinomas","volume":"11","author":"Arildsen","year":"2020","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib86","article-title":"\"Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells","volume":"2014","author":"Gong","year":"2014","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib87","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1080\/01635581.2022.2049321","article-title":"\"Molecular targets of curcumin and its therapeutic potential for ovarian cancer","volume":"74","author":"Mohamadian","year":"2022","journal-title":"Nutr. Cancer"},{"issue":"10023","key":"10.1016\/j.biopha.2025.118885_bib88","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"\"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib89","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2022.10.012","article-title":"\"Looking beyond carboplatin and paclitaxel for the treatment of advanced\/recurrent endometrial cancer","volume":"167","author":"Rubinstein","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.maturitas.2016.05.013","article-title":"\"Hormone replacement therapy and the risk of endometrial cancer: a systematic review","volume":"91","author":"Sj\u00f6gren","year":"2016","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib91","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/01443615.2019.1588238","article-title":"\"Arsenic trioxide in the treatment of platinum-resistant recurrent endometrial cancer: a case report and literature review","volume":"40","author":"Cai","year":"2020","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.biopha.2025.118885_bib92","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1007\/s12272-019-01190-5","article-title":"\"Potential molecular mechanisms underlying the effect of arsenic on angiogenesis","volume":"42","author":"Zhang","year":"2019","journal-title":"Arch. pharmacal Res."},{"key":"10.1016\/j.biopha.2025.118885_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-0861-5","article-title":"\"Patient-Derived Xenografts Faithfully Replicated Clinical Outcome in a Phase Ii Co-Clinical Trial of Arsenic Trioxide in Relapsed Small Cell Lung Cancer","volume":"14","author":"Owonikoko","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118885_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110177","article-title":"\"Combination Treatment with cyclosporin a and arsenic trioxide induce synergistic cell death via non-apoptotic pathway in uterine cervical cancer cells","volume":"368","author":"Wu","year":"2022","journal-title":"Chem. Biol. Interact."},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib95","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1933719108324134","article-title":"\"Arsenic trioxide (as2o3) inhibits expression of estrogen receptor\u2014alpha through regulation of the mitogen-activated protein kinase (mapk) pathway in endometrial cancer cells","volume":"15","author":"Bae-Jump","year":"2008","journal-title":"Reprod. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118885_bib96","first-page":"2708","article-title":"\"Alendronate inhibits invasion of pc-3 prostate cancer cells by affecting the mevalonate pathway.\"","volume":"62","author":"Virtanen","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib97","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ygyno.2014.02.014","article-title":"\"The effect of bisphosphonates on the risk of endometrial and ovarian malignancies","volume":"133","author":"Rennert","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib98","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/pds.4075","article-title":"\"Bisphosphonate use and the risk of endometrial cancer: a meta-analysis of observational studies","volume":"10","author":"Ou","year":"2016","journal-title":"Pharmacoepidemiol. Drug Saf. 25"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib99","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ctrv.2008.09.003","article-title":"\"Her2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors","volume":"35","author":"Nielsen","year":"2009","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2025.118885_bib100","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1080\/03007995.2022.2112872","article-title":"\"Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States","volume":"38","author":"Liu","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"issue":"11","key":"10.1016\/j.biopha.2025.118885_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005607","article-title":"\"The clinical landscape of antibody-drug conjugates in endometrial cancer","volume":"34","author":"Fuc\u00e0","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib102","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.22.00628","article-title":"\"A Phase Ii, two-stage study of letrozole and abemaciclib in estrogen receptor\u2013positive recurrent endometrial cancer","volume":"41","author":"Konstantinopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib103","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/j.ygyno.2024.07.425","article-title":"\"Nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer: a phase ii, open-label, single-arm, prospective, multicenter study","volume":"190","author":"Dockery","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2025.118885_bib104","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1200\/JCO.2010.34.1578","article-title":"\"Phase Ii study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the ncic clinical trials group","volume":"29","author":"Oza","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib105","first-page":"1","article-title":"\"Statin use and the risk of ovarian and endometrial cancers: a meta-analysis","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib106","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1158\/1940-6207.CAPR-22-0374","article-title":"\"The Role Of Statins In The Prevention Of Ovarian And Endometrial Cancers","volume":"16","author":"Zeleznik","year":"2023","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.biopha.2025.118885_bib107","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.1007\/s11033-020-05760-5","article-title":"\"Beyond lipid-lowering: role of statins in endometrial cancer","volume":"47","author":"Hafizz","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.biopha.2025.118885_bib108","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/1440-1681.12385","article-title":"\"Targeting Na+\/K+-translocating adenosine triphosphatase in cancer treatment","volume":"5","author":"Durlacher","year":"2015","journal-title":"Clin. Exp. Pharmacol. Physiol. 42"},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib109","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","article-title":"\"Human papillomavirus and cervical cancer","volume":"40","author":"Okunade","year":"2020","journal-title":"J. Obstet. Gynaecol."},{"key":"10.1016\/j.biopha.2025.118885_bib110","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005579","article-title":"\"Cervical Cancer: A New Era","author":"Caruso","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib111","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cac2.12629","article-title":"\"Advances in cervical cancer: current insights and future directions","volume":"45","author":"Xu","year":"2025","journal-title":"Cancer Commun."},{"issue":"11","key":"10.1016\/j.biopha.2025.118885_bib112","article-title":"\"Drug repurposing as a potential source of innovative therapies in cervical cancer","volume":"32","author":"Paul","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2025.118885_bib113","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s10637-017-0547-8","article-title":"\"Drug Repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (cafs) by synergistic induction of apoptosis","volume":"36","author":"Lee","year":"2018","journal-title":"Investig. N. Drugs"},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2012.10.021","article-title":"\"Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting er stress and chop expression","volume":"128","author":"Brem","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ygyno.2007.04.016","article-title":"\"Arsenic trioxide (as2o3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo","volume":"106","author":"Yu","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib116","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.7150\/thno.56747","article-title":"\"The double-edged roles of ros in cancer prevention and therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.biopha.2025.118885_bib117","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1158\/1078-0432.CCR-13-1121","article-title":"\"Cidofovir: a novel antitumor agent for glioblastoma","volume":"19","author":"Hadaczek","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib118","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1755-8794-6-18","article-title":"\"Cidofovir selectivity is based on the different response of normal and cancer cells to DNA Damage","volume":"6","author":"De Schutter","year":"2013","journal-title":"BMC Med. Genom."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib119","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ijgc-2021-002529","article-title":"\"Combined modality including novel sensitizers in gynecological cancers","volume":"32","author":"Zhou","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"36","key":"10.1016\/j.biopha.2025.118885_bib120","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.23.00914","article-title":"\"First-Line pembrolizumab+ chemotherapy versus placebo+ chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of keynote-826","volume":"41","author":"Monk","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115146","article-title":"\"Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase iii empower-cervical 1\/Gog-3016\/Engot-Cx9 Trial","volume":"216","author":"Oaknin","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib122","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1053\/j.jvca.2023.11.020","article-title":"\"Safety of levosimendan in pediatric patients: an up-to-date systematic review","volume":"38","author":"Pilia","year":"2024","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"issue":"7","key":"10.1016\/j.biopha.2025.118885_bib123","doi-asserted-by":"crossref","first-page":"6566","DOI":"10.3390\/cimb46070391","article-title":"\"An in vitro investigation of the antiproliferative and antimetastatic effects of levosimendan: potential drug repurposing for cervical cancer","volume":"46","author":"Schelz","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib124","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1476-5381.2008.00024.x","article-title":"\"Levosimendan induces no production through p38 mapk, erk and akt in porcine coronary endothelial cells: role for mitochondrial katp channel","volume":"156","author":"Grossini","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118885_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107706","article-title":"\"Artemisinins as a novel anti-cancer therapy: targeting a global cancer pandemic through drug repurposing","volume":"216","author":"Augustin","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2024.14447","article-title":"\"Artesunate promotes cervical cancer cell apoptosis by regulating bcl2 family molecules and reducing the mitochondrial membrane potential","volume":"28","author":"Zhang","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2025.118885_bib127","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10495-012-0717-2","article-title":"\"Thioridazine induces apoptosis by targeting the pi3k\/akt\/mtor pathway in cervical and endometrial cancer cells","volume":"17","author":"Kang","year":"2012","journal-title":"Apoptosis"},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib128","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jog.12691","article-title":"\"Dopamine d2 receptor blocker thioridazine induces cell death in human uterine cervical carcinoma cell line siha","volume":"41","author":"Mao","year":"2015","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.biopha.2025.118885_bib129","first-page":"53","article-title":"\"Decitabine in the treatment of acute myeloid leukemia in elderly patients","author":"Malik","year":"2014","journal-title":"Cancer Manag. Res."},{"issue":"17","key":"10.1016\/j.biopha.2025.118885_bib130","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1002\/cncr.25204","article-title":"\"A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer","volume":"116","author":"Fang","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib131","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000421-200210000-00015","article-title":"\"Phase Ii Trial of Cisplatin Plus Decitabine, a New DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix","volume":"25","author":"Pohlmann","year":"2002","journal-title":"Am. J. Clin. Oncol."},{"issue":"32","key":"10.1016\/j.biopha.2025.118885_bib132","doi-asserted-by":"crossref","first-page":"52104","DOI":"10.18632\/oncotarget.10631","article-title":"\"5-Aza-2\u2032-Deoxycytidine (Dac) Treatment Downregulates the Hpv E6 and E7 oncogene expression and blocks neoplastic growth of Hpv-associated cancer cells","volume":"8","author":"Stich","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2025.118885_bib133","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ijgo.13881","article-title":"\"Cancer of the vulva: 2021 update","author":"Olawaiye","year":"2021","journal-title":"Int. J. Gynecol. Obstet. 155"},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib134","doi-asserted-by":"crossref","first-page":"986","DOI":"10.4161\/hv.27682","article-title":"\"Risk of Cervical Hpv infection and prevalence of vaccine-type and other high-risk hpv types among sexually active teens and young women (13\u201326 years) enrolled in the valhidate study","volume":"10","author":"Orlando","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.biopha.2025.118885_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2022.107302","article-title":"\"Trends in hpv-and non-hpv-associated vulvar cancer incidence, United States, 2001\u20132017","volume":"164","author":"Mix","year":"2022","journal-title":"Prev. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118885_bib136","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bbagrm.2019.01.001","article-title":"\"Hallmarks of hpv carcinogenesis: the role of e6, e7 and e5 oncoproteins in cellular malignancy","volume":"1862","author":"Est\u00eav\u00e3o","year":"2019","journal-title":"Biochimica et Biophysica Acta (BBA)Gene Regulatory Mechanisms"},{"issue":"7","key":"10.1016\/j.biopha.2025.118885_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2023-004486","article-title":"\"European society of gynaecological oncology guidelines for the management of patients with vulvar cancer-update 2023","volume":"33","author":"Oonk","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2025.118885_bib138","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1200\/JCO.23.02235","article-title":"\"Phase Ii trial of cisplatin, gemcitabine, and intensity-modulated radiation therapy for locally advanced vulvar squamous cell carcinoma: Nrg Oncology\/Gog Study 279","volume":"42","author":"Horowitz","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib139","article-title":"Christian Naujokat,\u201cClinical activity of salinomycin in humanadvanced vulvar cancer","author":"Steinhart","year":"2013","journal-title":"Case Rep. Oncol."},{"issue":"31","key":"10.1016\/j.biopha.2025.118885_bib140","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"\"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase i\/ii checkmate 358 Trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005523","article-title":"\"Apollo: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma\u2014a multicenter, single-arm, phase ii, clinical proof-of-concept study","author":"van Poelgeest","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2025.118885_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5511","article-title":"\"Primary results of a phase 2 study of cisplatin-sensitized radiation therapy and pembrolizumab for unresectable vulvar cancer","author":"Yeku","year":"2025","journal-title":"Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib143","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ijc.30733","article-title":"\"Metformin and the incidence of viral associated cancers in patients with type 2 diabetes","volume":"141","author":"Hicks","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib144","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.ygyno.2014.04.007","article-title":"\"Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials","volume":"133","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib145","series-title":"In Artificial Intelligence and Bioinformatics in Cancer: An Interdisciplinary Approach","first-page":"271","article-title":"\"Signature-Based Drug Repositioning: Tackling Speeding up Drug Discovery of Anticancer Drugs Employing Recently Developed Machine Learning Tools","author":"El-Gawad","year":"2024"},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib146","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/cells12050794","article-title":"\"An Innovative Drug Repurposing Approach to Restrain Endometrial Cancer Metastatization","volume":"12","author":"Torricelli","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118885_bib147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4035-0","article-title":"\"Preclinical evaluation and reverse phase protein array-based profiling of pi3k and mek inhibitors in endometrial carcinoma in vitro","volume":"18","author":"Aslan","year":"2018","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib148","article-title":"\"Pi3k\/Akt\/mtor inhibitors for advanced or recurrent endometrial cancer","author":"Roncolato","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib149","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ygyno.2015.04.005","article-title":"\"A Phase Ii Evaluation of Selumetinib (Azd6244, Arry-142886), a Selective Mek-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an nrg oncology\/gynecologic oncology group study","volume":"138","author":"Coleman","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib150","unstructured":"Irham, Lalu Muhammad, Renardy Reza Razali Winarto, Wiwit Ade Fidiawati, Auren Nathania, and Leina Putri Zahra. \"Repurposing Drugs in Endometrial Cancer Using Genomic Variants Database.\""},{"key":"10.1016\/j.biopha.2025.118885_bib151","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.745590","article-title":"\"Identification of novel drug candidate for epithelial ovarian cancer via in silico investigation and in vitro validation.\"","volume":"11","author":"Zou","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2025.118885_bib152","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11224-019-01378-x","article-title":"\"Drug repurposing approach for the identification and designing of potential e6 inhibitors against cervical cancer: an in silico investigation","volume":"31","author":"Kumar","year":"2020","journal-title":"Struct. Chem."},{"key":"10.1016\/j.biopha.2025.118885_bib153","first-page":"1","article-title":"\"Screening and identification of potential inos inhibitors to curtail cervical cancer progression: an in silico drug repurposing approach","author":"Poleboyina","year":"2022","journal-title":"Appl. Biochem. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118885_bib154","first-page":"1","article-title":"\"Molecular regulator driving endometriosis towards endometrial cancer: a multi-scale computational investigation to repurpose anti-cancer drugs","author":"Mahema","year":"2024","journal-title":"Cell Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41698-017-0029-7","article-title":"\"Network-based machine learning and graph theory algorithms for precision oncology","volume":"1","author":"Zhang","year":"2017","journal-title":"NPJ Precis. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib156","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67163-x","article-title":"\"Explainable drug repurposing via path based knowledge graph completion","volume":"14","author":"Jim\u00e9nez","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib157","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1021\/acs.jcim.1c00009","article-title":"\"Pathway-based drug repurposing with dpnetinfer: a method to predict drug\u2013pathway associations via network-based approaches","volume":"61","author":"Wang","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib158","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/med.21802","article-title":"\"Pharmaceuticals targeting signaling pathways of endometriosis as potential new medical treatment: a review","volume":"41","author":"Hung","year":"2021","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2025.118885_bib159","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820980112","article-title":"Screening and discovery of new potential biomarkers and small molecule drugs for cervical cancer: a bioinformatics analysis","volume":"19","author":"Qiu","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"issue":"D1","key":"10.1016\/j.biopha.2025.118885_bib160","doi-asserted-by":"crossref","first-page":"D607","DOI":"10.1093\/nar\/gky1131","article-title":"\"String V11: protein\u2013protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets","volume":"47","author":"Szklarczyk","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2025.118885_bib161","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40199-021-00413-9","article-title":"\"Repurposing new drug candidates and identifying crucial molecules underlying pcos pathogenesis based on bioinformatics analysis","volume":"29","author":"Dehghan","year":"2021","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2025.118885_bib162","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.1016\/j.csbj.2023.10.038","article-title":"\"Network-based drug repurposing for hpv-associated cervical cancer","volume":"21","author":"Ahmed","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"47","key":"10.1016\/j.biopha.2025.118885_bib163","doi-asserted-by":"crossref","first-page":"E11138","DOI":"10.1073\/pnas.1801156115","article-title":"\"Vorinostat, a pan-hdac inhibitor, abrogates productive Hpv-18 DNA Amplification","volume":"115","author":"Banerjee","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2025.118885_bib164","first-page":"1","article-title":"\"Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer","author":"Ahmed","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.biopha.2025.118885_bib165","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.artmed.2017.03.009","article-title":"\"Drug repositioning based on triangularly balanced structure for tissue-specific diseases in incomplete interactome","volume":"77","author":"Yu","year":"2017","journal-title":"Artif. Intell. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib166","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/onc.2017.328","article-title":"\"Using a novel computational drug-repositioning approach (drugpredict) to rapidly identify potent drug candidates for cancer treatment","volume":"37","author":"Nagaraj","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib167","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13278-020-00660-9","article-title":"\"A comparative analysis of similarity measures akin to the jaccard index in collaborative recommendations: empirical and theoretical perspective","volume":"10","author":"Verma","year":"2020","journal-title":"Soc. Netw. Anal. Min."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib168","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ajhg.2017.06.005","article-title":"\"10 years of gwas discovery: biology, function, and translation","volume":"101","author":"Visscher","year":"2017","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib169","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molp.2016.12.008","article-title":"\"Genome-wide association studies in maize: praise and stargaze","volume":"10","author":"Xiao","year":"2017","journal-title":"Mol. Plant"},{"issue":"11","key":"10.1016\/j.biopha.2025.118885_bib170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1011490","article-title":"\"Gwas and 3d chromatin mapping identifies multicancer risk genes associated with hormone-dependent cancers","volume":"20","author":"Rivera","year":"2024","journal-title":"PLoS Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib171","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1038\/s41467-019-10744-6","article-title":"\"A genome-wide positioning systems network algorithm for in silico drug repurposing","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib172","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/amiajnl-2014-002649","article-title":"\"Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality","volume":"22","author":"Xu","year":"2015","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"10.1016\/j.biopha.2025.118885_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114518","article-title":"\"Machine learning for genetic prediction of chemotherapy toxicity in cervical cancer","volume":"161","author":"Guo","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib174","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s13167-024-00374-4","article-title":"\"Artificial intelligence in ovarian cancer drug resistance advanced 3pm approach: subtype classification and prognostic modeling","volume":"15","author":"Zhang","year":"2024","journal-title":"EPMA J."},{"issue":"6","key":"10.1016\/j.biopha.2025.118885_bib175","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/18735592MTEzsMDMnz","article-title":"\"Artificial intelligence, big data and machine learning approaches in precision medicine & drug discovery","volume":"22","author":"Nayarisseri","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.biopha.2025.118885_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"\"Machine and deep learning approaches for cancer drug repurposing","author":"Issa","year":"2021","journal-title":"Pap. Presente Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib177","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/s41598-024-52814-w","article-title":"\"Harnessing machine learning to find synergistic combinations for fda-approved cancer drugs","volume":"14","author":"Abd El-Hafeez","year":"2024","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib178","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/1061186X.2024.2365934","article-title":"\"Harnessing machine learning potential for personalised drug design and overcoming drug resistance","volume":"32","author":"Hakami","year":"2024","journal-title":"J. Drug Target."},{"key":"10.1016\/j.biopha.2025.118885_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115809","article-title":"\"High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric b-cell precursor acute lymphoblastic leukemia","volume":"217","author":"Oikonomou","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib180","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41597-024-03869-x","article-title":"\"High-throughput drug screening identifies novel therapeutics for low grade serous ovarian carcinoma","volume":"11","author":"Pishas","year":"2024","journal-title":"Sci. Data"},{"key":"10.1016\/j.biopha.2025.118885_bib181","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2024.06.029","article-title":"\"Preclinical 3d model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer","volume":"188","author":"Kumar","year":"2024","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118885_bib182","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"\"Phenotypic screening in cancer drug discovery\u2014past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118885_bib183","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/5584_2021_622","article-title":"\"Drug sensitivity and drug repurposing platform for cancer precision medicine","author":"Nweke","year":"2021","journal-title":"Cell biology translational medicine volume 12 Stem cells development disease"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib184","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s13048-024-01520-2","article-title":"\"In vitro drug testing using patient-derived ovarian cancer organoids","volume":"17","author":"Chen","year":"2024","journal-title":"J. Ovarian Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103422","article-title":"\"Drug repurposing using real-world data","volume":"28","author":"Tan","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.biopha.2025.118885_bib186","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"\"Drug Repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib187","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s43556-024-00204-z","article-title":"\"Repurposing metabolic regulators: antidiabetic drugs as anticancer agents","volume":"5","author":"Dhas","year":"2024","journal-title":"Mol. Biomed."},{"issue":"5","key":"10.1016\/j.biopha.2025.118885_bib188","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/1871520620666200120100252","article-title":"\"Therapeutic potentials and mechanisms of artemisinin and its derivatives for tumorigenesis and metastasis","volume":"20","author":"Li","year":"2020","journal-title":"AntiCancer Agents Medicinal Chemistry (Formerly Current Medicinal ChemistryAntiCancer Agents)"},{"issue":"4","key":"10.1016\/j.biopha.2025.118885_bib189","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2217\/fon.13.228","article-title":"\"Use of artemisinin and its derivatives to treat hpv-infected\/transformed cells and cervical cancer: a review","volume":"10","author":"Goodrich","year":"2014","journal-title":"Future Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib190","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3390\/app11010222","article-title":"\"Ibrutinib could suppress ca-125 in ovarian cancer: a hypothesis","volume":"11","author":"Metzler","year":"2020","journal-title":"Appl. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib191","first-page":"403","article-title":"\"The 505 (B)(2) Drug approval pathway.\"","volume":"74","author":"Darrow","year":"2019","journal-title":"Food Drug Law J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib192","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"\"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2025.118885_bib193","doi-asserted-by":"crossref","unstructured":"Schoonderbeek, Carla, and Bart Jong. \"Regulatory Exclusivities for Medicinal Products for Human Use in the Eu.\" 5-8: Taylor & Francis, 2016.","DOI":"10.4155\/ppa.15.35"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib194","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1071\/AH24077","article-title":"\"The medicines repurposing program\u2013a critical perspective","volume":"48","author":"Ghinea","year":"2024","journal-title":"Aust. Health Rev."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib195","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1186\/s13063-022-06713-y","article-title":"\"Identifying obstacles hindering the conduct of academic-sponsored trials for drug repurposing on rare-diseases: an analysis of six use cases","volume":"23","author":"Del \u00c1lamo","year":"2022","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib196","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cpt.2480","article-title":"\"Use of real-world evidence to drive drug development strategy and inform clinical trial design","volume":"111","author":"Dagenais","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118885_bib197","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/21678707.2017.1264300","article-title":"\"Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials","volume":"5","author":"Mandilaras","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib198","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2018.04.008","article-title":"\"Clinical trial methodology in rare gynecologic tumor research: strategies for success","volume":"149","author":"Brown","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118885_bib199","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.arcmed.2020.10.021","article-title":"\"Drug Repurposing: Considerations to surpass while re-directing old compounds for new treatments","volume":"52","author":"Ju\u00e1rez-L\u00f3pez","year":"2021","journal-title":"Arch. Med. Res."},{"issue":"612","key":"10.1016\/j.biopha.2025.118885_bib200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd5524","article-title":"\"Drug Repurposing: misconceptions, challenges, and opportunities for academic researchers","volume":"13","author":"Begley","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2025.118885_bib201","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/bs.pmbts.2024.03.019","article-title":"Regulatory considerations and intellectual property rights of repurposed drugs","volume":"205","author":"Afzaal","year":"2024","journal-title":"Prog. Mol. Biol. Transl. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T07:04:20Z","timestamp":1777014260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":201,"alternative-id":["S0753332225010790"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118885","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug repurposing in gynaecological cancers: Proven drugs for new challenges","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118885"}}